AXSOME THERAPEUTICS, INC. (AXSM) Free cash flow
- Free cash flow · 12 months (USD): Value $-71.96M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -9.27%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-71.96M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-71.26M − $700.00K ≈ $-71.96M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -9.27% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-71.96M ÷ $776.57M × 100 ≈ -9.27% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-71.26M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.37× | Operating cash flow / net income. Period ending 2026-06-30. $-71.26M ÷ $-191.64M ≈ 0.37× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -71.26M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 700.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -71.96M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 776.57M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -191.64M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-71.96M | (m) | $-71.26M | $700.00K | (m) | $776.57M | (m) | $-191.64M | (m) | (m) | -9.27% | 0.37× |
| 2026-03-31 | $-70.99M | (m) | $-70.73M | $263.00K | (m) | $708.24M | (m) | $-188.30M | (m) | (m) | -10.02% | 0.38× |
| 2025-12-31 | $-93.89M | (m) | $-93.41M | $480.00K | (m) | $638.50M | (m) | $-183.17M | (m) | (m) | -14.70% | 0.51× |
| 2025-09-30 | $-101.39M | (m) | $-100.95M | $439.00K | (m) | $561.26M | (m) | $-229.53M | (m) | (m) | -18.07% | 0.44× |
| 2025-06-30 | $-121.10M | (m) | $-120.63M | $471.00K | (m) | $495.03M | (m) | $-246.90M | (m) | (m) | -24.46% | 0.49× |
| 2025-03-31 | $-118.83M | (m) | $-118.32M | $510.00K | (m) | $432.16M | (m) | $-278.27M | (m) | (m) | -27.50% | 0.43× |
| 2024-12-31 | $-128.68M | (m) | $-128.41M | $270.00K | (m) | $385.69M | (m) | $-287.22M | (m) | (m) | -33.36% | 0.45× |
| 2024-09-30 | $-132.82M | (m) | $-132.57M | $247.00K | (m) | $338.46M | (m) | $-310.95M | (m) | (m) | -39.24% | 0.43× |
| 2024-06-30 | $-168.01M | (m) | $-167.49M | $528.00K | (m) | $291.49M | (m) | $-308.55M | (m) | (m) | -57.64% | 0.54× |
| 2024-03-31 | $-193.34M | (m) | $-192.73M | $609.00K | (m) | $251.02M | (m) | $-296.38M | (m) | (m) | -77.02% | 0.65× |
| 2023-12-31 | $-145.66M | (m) | $-145.08M | $582.00K | (m) | $270.60M | (m) | $-239.24M | (m) | (m) | -53.83% | 0.61× |
| 2023-09-30 | $-143.04M | (m) | $-142.28M | $756.11K | (m) | $223.44M | (m) | $-201.83M | (m) | (m) | -64.02% | 0.70× |
| 2023-06-30 | $-111.94M | (m) | $-111.49M | $451.11K | (m) | $182.49M | (m) | $-184.45M | (m) | (m) | -61.34% | 0.60× |
| 2023-03-31 | $-90.24M | (m) | $-89.68M | $559.11K | (m) | $144.61M | (m) | $-158.72M | (m) | (m) | -62.40% | 0.57× |
| 2022-12-31 | $-117.21M | (m) | $-116.51M | $702.11K | (m) | $50.04M | (m) | $-187.13M | (m) | (m) | -234.25% | 0.62× |
| 2022-09-30 | $-118.31M | (m) | $-117.79M | $521.25K | (m) | (m) | (m) | $-159.87M | (m) | (m) | (m) | 0.74× |
| 2022-06-30 | $-122.52M | (m) | $-121.81M | $713.87K | (m) | (m) | (m) | $-149.93M | (m) | (m) | (m) | 0.81× |
| 2022-03-31 | $-114.15M | (m) | $-113.66M | $491.29K | (m) | (m) | (m) | $-140.78M | (m) | (m) | (m) | 0.81× |
| 2021-12-31 | $-108.53M | (m) | $-108.23M | $307.55K | (m) | (m) | (m) | $-130.40M | (m) | (m) | (m) | 0.83× |
| 2021-09-30 | $-100.27M | (m) | $-99.94M | $327.84K | (m) | (m) | (m) | $-125.59M | (m) | (m) | (m) | 0.80× |
| 2021-06-30 | $-88.98M | (m) | $-88.90M | $84.00K | (m) | (m) | (m) | $-113.63M | (m) | (m) | (m) | 0.78× |
| 2021-03-31 | $-82.47M | (m) | $-82.40M | $66.56K | (m) | (m) | (m) | $-99.68M | (m) | (m) | (m) | 0.83× |
| 2020-12-31 | $-78.50M | (m) | $-78.46M | $45.89K | (m) | (m) | (m) | $-102.90M | (m) | (m) | (m) | 0.76× |
| 2020-09-30 | $-75.50M | (m) | $-75.47M | $27.07K | (m) | (m) | (m) | $-98.54M | (m) | (m) | (m) | 0.77× |
| 2020-06-30 | $-70.38M | (m) | $-70.36M | $15.42K | (m) | (m) | (m) | $-94.75M | (m) | (m) | (m) | 0.74× |
| 2020-03-31 | (m) | (m) | $-60.15M | (m) | (m) | (m) | (m) | $-90.19M | (m) | (m) | (m) | 0.67× |
| 2019-12-31 | $-46.39M | (m) | $-46.38M | $16.12K | (m) | (m) | (m) | $-68.35M | (m) | (m) | (m) | 0.68× |
| 2019-09-30 | $-38.62M | (m) | $-38.60M | $14.66K | (m) | (m) | (m) | $-53.14M | (m) | (m) | (m) | 0.73× |
| 2019-06-30 | $-33.91M | (m) | $-33.89M | $19.95K | (m) | (m) | (m) | $-42.28M | (m) | (m) | (m) | 0.80× |
| 2019-03-31 | (m) | (m) | $-32.87M | (m) | (m) | (m) | (m) | $-36.80M | (m) | (m) | (m) | 0.89× |
| 2018-12-31 | $-30.09M | (m) | $-30.05M | $32.70K | (m) | (m) | (m) | $-30.97M | (m) | (m) | (m) | 0.97× |
| 2018-09-30 | $-26.58M | (m) | $-26.55M | $32.70K | (m) | (m) | (m) | $-28.80M | (m) | (m) | (m) | 0.92× |
| 2018-06-30 | $-27.11M | (m) | $-27.09M | $27.82K | (m) | (m) | (m) | $-26.95M | (m) | (m) | (m) | 1.01× |
| 2018-03-31 | $-26.54M | (m) | $-26.52M | $21.57K | (m) | (m) | (m) | $-25.75M | (m) | (m) | (m) | 1.03× |
| 2017-12-31 | $-26.48M | (m) | $-26.47M | $9.90K | (m) | (m) | (m) | $-28.94M | (m) | (m) | (m) | 0.91× |
| 2017-09-30 | $-27.41M | (m) | $-27.40M | $15.95K | (m) | (m) | (m) | $-28.84M | (m) | (m) | (m) | 0.95× |
| 2017-06-30 | $-25.84M | (m) | $-25.75M | $88.60K | (m) | (m) | (m) | $-29.60M | (m) | (m) | (m) | 0.87× |
| 2017-03-31 | $-24.07M | (m) | $-23.97M | $96.81K | (m) | (m) | (m) | $-29.33M | (m) | (m) | (m) | 0.82× |
| 2016-12-31 | $-21.39M | (m) | $-21.28M | $104.56K | (m) | (m) | (m) | $-27.20M | (m) | (m) | (m) | 0.78× |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-7.46M | (m) | $-7.44M | $20.20K | (m) | (m) | (m) | $-12.21M | (m) | (m) | (m) | 0.61× |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $-4.60M | (m) | (m) | (m) | (m) | $-6.00M | (m) | (m) | (m) | 0.77× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |